While glucose metabolism in group 3 medulloblastomas and MycN-driven medulloblastomas in mice have yet to be investigated, it is likely that MYC reconfigures the metabolism to favor glycolysis in these tumors, as it does in other malignancies. The gene discussed is MYCN; the disease is medulloblastoma.